Tiago Fauth
Stock Analyst at Wells Fargo
(2.04)
# 2,928
Out of 4,900 analysts
140
Total ratings
37.84%
Success rate
-7.02%
Average return
Main Sectors:
Stocks Rated by Tiago Fauth
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $88 → $65 | $27.20 | +138.97% | 8 | Jul 10, 2025 | |
| VRNA Verona Pharma | Downgrades: Equal-Weight | $138 → $107 | $104.77 | +2.13% | 7 | Jul 10, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $67 → $76 | $46.97 | +61.82% | 1 | Jun 30, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $287 → $333 | $311.12 | +7.03% | 6 | Jun 30, 2025 | |
| LQDA Liquidia | Maintains: Overweight | $23 → $25 | $14.51 | +72.29% | 2 | Jun 12, 2025 | |
| INSM Insmed | Maintains: Overweight | $107 → $119 | $102.87 | +15.68% | 5 | Jun 11, 2025 | |
| SVRA Savara | Maintains: Overweight | $8 → $7 | $2.29 | +205.68% | 2 | May 28, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $68 → $74 | $47.75 | +54.97% | 2 | May 27, 2025 | |
| UTHR United Therapeutics | Downgrades: Equal-Weight | $395 → $314 | $293.24 | +7.08% | 5 | Apr 25, 2025 | |
| TECX Tectonic Therapeutic | Maintains: Overweight | $112 → $101 | $21.57 | +368.24% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $3 | $1.39 | +115.83% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $14.25 | +82.46% | 6 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $17 | $5.91 | +187.65% | 1 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $3.85 | +133.77% | 1 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $22 | $7.71 | +185.34% | 2 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $75 | $56.29 | +33.24% | 1 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $62 | $3.03 | +1,946.20% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $89 | $174.75 | -49.07% | 16 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $51 | $16.26 | +213.65% | 3 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $120 | $56.62 | +111.94% | 7 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $4 | $17.49 | -77.13% | 4 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $2.57 | +444.75% | 4 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $6.13 | +324.14% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $28 | $3.94 | +610.66% | 7 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $81 | $19.35 | +318.60% | 11 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $0.39 | +1,930.97% | 5 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.16 | +1,106.90% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $34 | $0.47 | +7,188.32% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $150 | $3.55 | +4,121.19% | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $44.06 | -34.18% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $1.95 | +566.67% | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $13 | $2.75 | +372.73% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2.5 → $2 | $0.81 | +145.70% | 4 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $297 → $340 | $554.71 | -38.71% | 3 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $265 → $259 | $292.51 | -11.46% | 1 | Apr 28, 2021 |
Ultragenyx Pharmaceutical
Jul 10, 2025
Maintains: Overweight
Price Target: $88 → $65
Current: $27.20
Upside: +138.97%
Verona Pharma
Jul 10, 2025
Downgrades: Equal-Weight
Price Target: $138 → $107
Current: $104.77
Upside: +2.13%
BridgeBio Pharma
Jun 30, 2025
Maintains: Overweight
Price Target: $67 → $76
Current: $46.97
Upside: +61.82%
Alnylam Pharmaceuticals
Jun 30, 2025
Maintains: Equal-Weight
Price Target: $287 → $333
Current: $311.12
Upside: +7.03%
Liquidia
Jun 12, 2025
Maintains: Overweight
Price Target: $23 → $25
Current: $14.51
Upside: +72.29%
Insmed
Jun 11, 2025
Maintains: Overweight
Price Target: $107 → $119
Current: $102.87
Upside: +15.68%
Savara
May 28, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $2.29
Upside: +205.68%
PTC Therapeutics
May 27, 2025
Maintains: Overweight
Price Target: $68 → $74
Current: $47.75
Upside: +54.97%
United Therapeutics
Apr 25, 2025
Downgrades: Equal-Weight
Price Target: $395 → $314
Current: $293.24
Upside: +7.08%
Tectonic Therapeutic
Mar 21, 2025
Maintains: Overweight
Price Target: $112 → $101
Current: $21.57
Upside: +368.24%
Mar 4, 2025
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $1.39
Upside: +115.83%
Feb 27, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $14.25
Upside: +82.46%
Feb 20, 2025
Maintains: Overweight
Price Target: $18 → $17
Current: $5.91
Upside: +187.65%
Dec 20, 2024
Initiates: Overweight
Price Target: $9
Current: $3.85
Upside: +133.77%
Oct 16, 2024
Maintains: Overweight
Price Target: $11 → $22
Current: $7.71
Upside: +185.34%
Aug 22, 2024
Initiates: Overweight
Price Target: $75
Current: $56.29
Upside: +33.24%
Aug 11, 2023
Maintains: Outperform
Price Target: $63 → $62
Current: $3.03
Upside: +1,946.20%
Jun 14, 2023
Assumes: Neutral
Price Target: $89
Current: $174.75
Upside: -49.07%
Jun 14, 2023
Assumes: Outperform
Price Target: $51
Current: $16.26
Upside: +213.65%
Jun 14, 2023
Assumes: Outperform
Price Target: $120
Current: $56.62
Upside: +111.94%
May 23, 2023
Reiterates: Underperform
Price Target: $4
Current: $17.49
Upside: -77.13%
May 16, 2023
Reiterates: Outperform
Price Target: $14
Current: $2.57
Upside: +444.75%
May 11, 2023
Reiterates: Outperform
Price Target: $26
Current: $6.13
Upside: +324.14%
May 5, 2023
Maintains: Outperform
Price Target: $34 → $28
Current: $3.94
Upside: +610.66%
May 5, 2023
Maintains: Neutral
Price Target: $70 → $81
Current: $19.35
Upside: +318.60%
Mar 24, 2023
Reiterates: Neutral
Price Target: $8
Current: $0.39
Upside: +1,930.97%
Mar 23, 2023
Reiterates: Outperform
Price Target: $14
Current: $1.16
Upside: +1,106.90%
Mar 10, 2023
Maintains: Outperform
Price Target: $38 → $34
Current: $0.47
Upside: +7,188.32%
Mar 10, 2023
Reiterates: Outperform
Price Target: $150
Current: $3.55
Upside: +4,121.19%
Jan 26, 2023
Initiates: Outperform
Price Target: $29
Current: $44.06
Upside: -34.18%
Dec 16, 2022
Initiates: Outperform
Price Target: $13
Current: $1.95
Upside: +566.67%
Nov 18, 2022
Downgrades: Neutral
Price Target: $25 → $13
Current: $2.75
Upside: +372.73%
May 13, 2022
Maintains: Underperform
Price Target: $2.5 → $2
Current: $0.81
Upside: +145.70%
Dec 20, 2021
Maintains: Neutral
Price Target: $297 → $340
Current: $554.71
Upside: -38.71%
Apr 28, 2021
Maintains: Outperform
Price Target: $265 → $259
Current: $292.51
Upside: -11.46%